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Background
Osel is developing a live microbicide, employing H2O2-
producing Lactobacillus jensenii 1153, a natural compo-
nent of human vaginal microflora, as a delivery vehicle.
Materials and methods
An expression cassette harboring native regulatory ele-
ments was optimized to secrete high levels of modified
cyanovirin-N (P51G) (CV-N). The expression cassette was
stably integrated into the bacterial chromosome.
Results
The CV-N-producing L. jensenii retained important char-
acteristics of the native bacterial phenotype and secreted
high levels of full-length CV-N that completely inhibited
the infectivity of CCR5-tropic HIVBaL in vitro, with an
IC50 near 1 nM. We further demonstrated that this strain
was capable of association with epithelial cells in the vag-
inal lumen of CD-1 mice, and expressed CV-N in vivo in
this model and when cultured in cervicovaginal lavage
fluid of pigtailed macaques. We are evaluating potential
regulatory issues, bacterial formulations, vaginal coloni-
zation, in situ CV-N expression, and host immunological
responses in non-human primate models.
Conclusion
This work represents a major step towards the develop-
ment of a simple, cost-effective, female-controlled pre-
ventative against heterosexual transmission of HIV.
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